Cormedix Inc.
A biopharmaceutical company that makes Defencath, a catheter lock solution used by kidney-dialysis patients to prevent bloodstream infections and blood clotting. Founded in 2006 by Antony P. Pfaffle, the firm began life as Picton Holding Company and was renamed CorMedix a few months later. The name blends the Latin "cor" (heart) with "medix," a nod to the medical conditions it addresses.
Granted 412.6K · Sold 80.0K
Granted 183.0K · Sold 54.0K
Granted 158.8K · Sold 50.0K
Granted 30.5K · Bought 25.0K
Granted 45.5K · Sold 40.0K
Granted 142.5K
Granted 133.2K
Granted 60.5K · Sold 30.0K
Granted 137.5K · Sold 147.0K
Granted 43.8K
Granted 30.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Todisco JosephChief Executive Officer, Director · 10 transactions | +52.1% | 774.7K | 412.6K | — | 80.0K |
| Hurlburt ElizabethChief Operating Officer · 10 transactions | +140.7% | 278.5K | 183.0K | — | 54.0K |
| Zelnick Kaufman BethChief Legal Officer · 8 transactions | +104.7% | 269.1K | 158.8K | — | 50.0K |
| Kaplan MyronDirector · 2 transactions | +26.9% | 261.5K | 30.5K | 25.0K | — |
| Lefkowitz Steven WDirector · 3 transactions | +3.6% | 158.1K | 45.5K | — | 40.0K |
| Blum SusanChief Financial Officer · 3 transactions | — | 142.5K | 142.5K | — | — |
| Seckler Michael DavidChief Commercial Officer · 1 transaction | — | 133.2K | 133.2K | — | — |
| Dunton Alan WDirector · 5 transactions | +75.7% | 70.7K | 60.5K | — | 30.0K |
| Dillione JanetDirector · 15 transactions | -12.2% | 68.9K | 137.5K | — | 147.0K |
| Duncan Gregory ScottDirector · 2 transactions | +175.1% | 68.8K | 43.8K | — | — |
| Stewart Robert ADirector · 1 transaction | +84.6% | 66.5K | 30.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -376.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.